A Randomized Controlled Phase 3 Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India

Condition:   Rotavirus Infection of Children Interventions:   Biological: TV P2-VP8;   Biological: Rotarix Sponsors:   PATH;   Bill and Melinda Gates Foundation;   SK Bioscience Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials